Cytyc announces $200 million four-year stock repurchase program

By Ted A. Knutson

Washington, Nov. 21 - Cytyc Corp. said its board of directors terminated the company's existing stock repurchase program and approved a new stock repurchase program for up to $200 million over a maximum of four years.

The repurchases will be made through open market purchases or private transactions that will be made from time to time as market conditions allow.

Shares repurchased under the new program will be held in the company's treasury and will be available for a variety of corporate purposes. The stock repurchase program may be suspended or discontinued at any time without prior notice, the company said.

Marlborough, Mass.-based Cytyc makes women's health products including devices for cervical cancer screening, breast cancer risk assessment, treatment of excessive menstrual bleeding, and treatment of breast cancer.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.